With a number of states complaining of vaccine shortage and temporarily shutting centres – at a time when the need is to increase the daily rate of jabs – the focus has intensified on the production and supply end of the chain.
Indications are that India’s vaccine production is expected to be limited for a few more weeks though a step-up is expected as Serum Institute of India and Bharat Biotech ramp up capacity, some of which is expected to be ready by next month, prompting the government to prioritise vaccinating segments that are seen to be more vulnerable.
Serum Institute, with a monthly capacity to produce 60-70 million doses, will increase production to nearly 100 million next month, which was its original target for January-February 2021. While it has supplied about 100 million doses so far for domestic use, this could cumulatively rise to about 470 million by August, depending on orders from the government.
J&J in talks with Centre for trial of single-shot Covid-19 vaccine
business-standard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from business-standard.com Daily Mail and Mail on Sunday newspapers.
Even as Covid vaccine demand rises, firms may take some weeks to up production | India News
indiatimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from indiatimes.com Daily Mail and Mail on Sunday newspapers.
First Quad Summit: One Billion Vaccine Doses For Asia, Cooperation on Approach to China
In a veiled reference to China, leaders at the the first Quad summit pledged to promote a âfree, open rules-based order, both in the Indo-Pacific and beyondâ.
President Joe Biden participated in a video summit with Indo-Pacific nation leaders at the White House. Photo: Tom Brenner/Reuters
Diplomacy13/Mar/2021
New Delhi: Meeting for the first time, the leaders of the four âQuadâ countries â India, Japan, United States and Australia, agreed to commit to manufacturing one billion doses of vaccine by 2022 for distribution in Asia, where Chinaâs presence casts a large shadow.